Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$25.39 USD
-0.93 (-3.53%)
Updated Oct 13, 2025 04:00 PM ET
After-Market: $25.45 +0.06 (0.24%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BEAM 25.39 -0.93(-3.53%)
Will BEAM be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BEAM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BEAM
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report?
BEAM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?
CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?
CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock
Other News for BEAM
Slingshot Bullish appears for BEAM after 5.56% move
Pocket Pivot appears for BEAM after 3.22% move
HC Wainwright & Co. Reiterates Buy Rating for BEAM at $80 Target | BEAM Stock News
H.C. Wainwright Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)
Beam Therapeutics initiated with a Buy at Jefferies